Joshua R. Disbrow Purchases 15,000 Shares of Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock

Aytu BioPharma, Inc. (NASDAQ:AYTU) CEO Joshua R. Disbrow acquired 15,000 shares of the firm’s stock in a transaction dated Friday, February 28th. The shares were purchased at an average price of $1.30 per share, with a total value of $19,500.00. Following the completion of the transaction, the chief executive officer now owns 86,591 shares of the company’s stock, valued at $112,568.30. This trade represents a 20.95 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Aytu BioPharma Trading Down 0.4 %

AYTU stock traded down $0.01 during midday trading on Monday, hitting $1.29. The stock had a trading volume of 32,830 shares, compared to its average volume of 26,010. The company has a current ratio of 0.98, a quick ratio of 0.81 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average price of $1.58 and a two-hundred day moving average price of $1.90. Aytu BioPharma, Inc. has a 1-year low of $1.23 and a 1-year high of $3.45. The firm has a market cap of $7.93 million, a P/E ratio of -0.89 and a beta of -1.45.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Wednesday, February 12th. The company reported ($0.28) EPS for the quarter. Aytu BioPharma had a negative net margin of 7.62% and a negative return on equity of 19.30%.

Hedge Funds Weigh In On Aytu BioPharma

An institutional investor recently raised its position in Aytu BioPharma stock. Stonepine Capital Management LLC lifted its stake in shares of Aytu BioPharma, Inc. (NASDAQ:AYTU) by 6.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 500,958 shares of the company’s stock after acquiring an additional 28,489 shares during the period. Aytu BioPharma accounts for about 0.7% of Stonepine Capital Management LLC’s portfolio, making the stock its 25th largest position. Stonepine Capital Management LLC owned approximately 8.15% of Aytu BioPharma worth $1,177,000 as of its most recent filing with the Securities & Exchange Commission. 33.49% of the stock is currently owned by institutional investors and hedge funds.

About Aytu BioPharma

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.